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NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
Heat Shock Protein 90 Inhibition in Lung Cancer
Takeshi Shimamura, PhD, and Geoffrey I. Shapiro, MD, PhD
The heat shock protein 90 (Hsp90) chaperone is required for the
conformational maturation and stability of multiple oncogenic ki-
nases that drive signal transduction and proliferation of lung cancer
cells. The recent demonstration that mutant epidermal growth factor
receptor is an Hsp90 client, irrespective of the presence of the
secondary threonine-to-methionine amino acid substitution mutation
at position 790 mediating anilinoquinazoline resistance, suggests
Hsp90 inhibition as a novel strategy against this group of lung
cancers. The rarer epidermal growth factor receptors harboring exon
20 insertions and vIII mutations are also Hsp90 clients. Lung
cancers may also be driven by mutant ErbB2, mutant B-Raf, or
mutant or overexpressed c-Met, all of which are also degraded on
Hsp90 inhibition. Hsp90 inhibitors may be synergistic with other
drugs that disrupt chaperone function, including inhibitors of histone
deacetylase 6 and the proteasome and agents that inhibit Hsp70
function. Hsp90 plays a unique antiapoptotic role in small cell lung
cancer cells, so that Hsp90 inhibition results in substantial cell death
in both chemosensitive and chemoresistant small cell lung cancer
cell lines. Clinically, the geldanamycin compounds are the most
mature, with manageable toxic effects. Several new classes of
Hsp90 inhibitors are emerging, including purines and pyrazoles that
have entered phase 1 trials. The available data suggest that Hsp90
inhibitors should be evaluated in multiple lung cancer subsets.
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The heat shock protein (Hsp90) chaperone and its associ-ated machinery mediate the conformational maturation of
several families of hormone receptors, transcription factors,
and kinases.1 In normal cells, levels of Hsp90 and other heat
shock proteins increase in response to stressors that cause
protein denaturation to promote normal protein folding and
cell survival.2,3 Hsp90 inhibition prevents its association with
client proteins; unfolded targets subsequently undergo ubiq-
uitin-mediated proteasomal degradation.4
Multiple mechanisms account for the potential selec-
tivity of Hsp90 inhibition for cancer cells over normal cells.
Cancer cells may be particularly dependent on chaperone
proteins to survive a hypoxic, nutrient-starved tumor micro-
environment.5,6 In addition, through the process of oncogene
addiction,7 cancer cells may be dependent on overexpressed
or mutant kinases for viability and hence particularly sensi-
tive to Hsp90 inhibition when the relevant kinases are Hsp90
clients.8,9 In this regard, many Hsp90-dependent proteins,
including the ErbB2, c-Met, and c-Kit receptor tyrosine
kinases; the v-src family of nonreceptor tyrosine kinases; the
serine-threonine kinases Raf-1, cdk4, Akt, and polo-like ki-
nase 1; and mutant p53 and human telomerase reverse tran-
scription, either are proto-oncogenic or contribute to dereg-
ulated signaling and proliferation in diverse human cancers.
The overexpression or mutation of these proteins leads to a
greater dependence on Hsp90 in cancer cells to ensure the
correct folding and function of large quantities of overex-
pressed oncoproteins and of mutant kinases with inherent
conformational instability. The chaperone dependence of mu-
tant kinases is illustrated by activated v-src and mutated
B-Raf, which are associated with an Hsp90 complex neces-
sary for correct folding and stability, whereas c-src and
wild-type B-Raf require only limited assistance from Hsp90
for maturation.10–12 Hsp90 inhibition results in degradation of
v-src or mutant B-Raf; in dependent cells, it inhibits signal
transduction and cell proliferation and induces apoptosis.
In addition, Hsp90 in tumor cells is found in multichap-
erone complexes with increased adenosine triphosphate (ATP)
activity, whereas Hsp90 from normal tissues is in a latent
uncomplexed state. In vitro reconstitution experiments have
demonstrated that Hsp90 complexes from tumor cells have
nearly 100-fold greater binding affinity for the ansamycin Hsp90
inhibitor 17-allylamino-17-demthoxygeldanamcyin (17-AAG)
compared with the uncomplexed form of Hsp90 in normal
cells.13 The nanomolar binding of 17-AAG to the ATP binding
site of high-affinity tumor Hsp90 is consistent with nanomolar
antitumor activity in preclinical models. The markedly higher
affinity of tumor Hsp90 also explains the ability of ansamycins
to accumulate at tumor sites in animals14,15 and suggests that
Hsp90 inhibition will demonstrate therapeutic selectivity for
cancer cells.
The recent demonstration that mutant epidermal growth
factor receptor (EGFR) is both associated with the Hsp90 chap-
erone and highly sensitive to degradation after Hsp90 inhibi-
tion16 has generated great interest in the use of Hsp90 inhib-
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itors in this lung cancer subgroup. In particular, Hsp90
inhibition may be useful for non-small cell lung cancers
(NSCLCs) expressing mutant EGFRs with either primary or
acquired resistance to EGFR tyrosine kinase inhibitors
(TKIs). In addition, in numerous cases, EGFR wild-type
NSCLCs may also be expected to depend on kinases that are
Hsp90 clients. Furthermore, Hsp90 inhibitors may be syner-
gistic with other agents that disrupt chaperone function or
inhibit Hsp70 activity. Finally, Hsp90 inhibitors may also be
useful in small cell lung cancer (SCLC), in which Hsp90
plays an essential antiapoptotic role. Here, we review the
evidence justifying assessment of Hsp90 inhibitors in various
lung cancer subsets and discuss the current status of Hsp90
inhibitors in clinical development.
HSP90 INHIBITION IN EGFR MUTANT NSCLC
NSCLC Harboring EGFR Kinase Domain
Mutation
Activating mutations in the kinase domain of EGFR,
present in approximately 10% of NSCLCs in the United
States, arise in four exons: G719 substitutions in the nucle-
otide-binding loop of exon 18, in-frame deletions within exon
19, in-frame insertions within exon 20, and substitutions for
L858 and L861 in the activation loop exon 21.17 Except for
exon 20 insertions, mutation confers sensitivity to the anili-
noquinazoline reversible EGFR TKIs gefitinib and erlo-
tinib.18–20 Responses are related to the enhanced association
of mutant EGFRs with TKIs, as well as to oncogene addic-
tion, such that EGFR inhibition suppresses an oncogenic
signal on which mutant NSCLC cells are dependent. Both
L858R and exon 19 deletion mutant EGFR proteins interact
with the chaperone and are depleted after Hsp90 inhibition.16
In isogenic NIH/3T3 cells that express either wild-type or
mutant EGFR, and in NSCLC cell lines, mutant EGFRs were
more sensitive to geldanamycin-induced degradation com-
pared with the wild-type protein. In EGFR-mutant cells,
geldanamycin caused marked depletion of phospho-Akt and
cyclin D1 and induced apoptosis. Association of mutant
EGFRs with Hsp90 not only confers conformational stability
but also protects from Cbl-mediated ubiquitination, impairing
ligand-induced receptor down-regulation by inhibiting recep-
tor endocytosis and lysosomal degradation.21
Of note, wild-type EGFR is depleted slowly from cells
after geldanamycin-mediated Hsp90 inhibition; therefore, it
is likely that there is transient association of nascent protein
with the chaperone, such that the decreased levels seen over
time represent compromised appearance of newly synthe-
sized protein. In contrast, similar to ErbB2 and other onco-
genic kinases,22 mature, membrane-bound mutant EGFR
likely maintains interaction and dependence on the chaper-
one, such that Hsp90 inhibition leads to rapid degradation and
more complete depletion. Therefore, Hsp90 function is es-
sential to maintain high-level expression of mutant EGFR in
NSCLC cells.
Mutant EGFR NSCLC with Primary Resistance
to Reversible EGFR TKIs
EGFR exon 20 insertion mutations represent only a
small percentage of EGFR mutations found in NSCLC (ap-
proximately 9%) and are therefore found in only 1 to 2% of
NSCLCs overall. Most EGFRs harboring exon 20 insertions
exhibit primary resistance to reversible EGFR TKIs.23 Al-
though no natural cell lines exist harboring EGFR exon 20
insertion mutations, several such mutants identified in pri-
mary patient samples have been expressed in COS7 cells.24 In
contrast to wild-type EGFR, Hsp90 was readily coimmuno-
precipitated with each of the mutant EGFRs, and this asso-
ciation was sensitive to brief exposure of cells to 17-AAG,
correlating with reduced expression of exon 20 insertion
mutant EGFR and its phosphorylated forms. The expression
of exon 20 insertion mutants led to up-regulation of endog-
enous Akt and/or Stat3 signaling proteins, and levels of
phospho-Akt and phospho-Stat3 were also reduced in 17-
AAG-treated cells.
EGFRs with Acquired Resistance to TKIs
Despite initial responses of EGFR-mutant tumors to
small-molecule TKIs, resistance universally emerges. Ac-
quired resistance is associated with a second somatic muta-
tion resulting in a threonine-to-methionine amino acid sub-
stitution at position 790 (T790M) of EGFR in approximately
50% of cases.25,26 T790M, when combined with activating
kinase domain mutations, confers enhanced catalytic phos-
phorylating activity and cooperates to produce a more potent
kinase.27
The primary approach under development for NSCLCs
expressing mutant EGFR harboring T790M mutation is the
use of irrreversible inhibitors that overcome deficient revers-
ible inhibitor binding because they contain a reactive group
that forms a covalent bond at the edge of the ATP binding
cleft. Preclinical studies have shown that the irreversible
EGFR inhibitor CL-387,785,28 the irreversible dual EGFR
and ErbB2 inhibitor HKI-272,29 and the irreversible pan-
ErbB inhibitor CI-103330 can overcome resistance to L858R-
mutated EGFR harboring the T790M resistance-conferring
mutation.
Recently, inducible murine lung adenocarcinoma mod-
els driven by expression of EGFR harboring L858R and
T790M mutations have been described.31,32 In contrast to
murine tumors driven by EGFR-L858R, in which only pe-
ripheral tumors occurred, both peripheral and bronchial tu-
mors developed in one of these models. Surprisingly, tumors
expressing L858R/T790M responded poorly to HKI-272.
These data reflect emerging clinical data with HKI-272,
indicating variable durations of stable disease but no re-
sponses among NSCLC patients previously treated with ge-
fitinib or erlotinib,33 and suggest the predictive value of these
mouse models. Further analysis indicated that mammalian
target of rapamycin (mTOR) signaling was weakly sup-
pressed by HKI-272, as measured by persistent robust phos-
phorylation of S6 after treatment. The limitation of HKI-272
in EGFR L858R/T790M-expressing cells was overcome by
the addition of rapamycin, so that combination treatment
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produced cytotoxic synergy in vitro and led to regressions in
vivo.31
The presence of the T790M mutation does not abrogate
the association of mutant EGFR with Hsp90 or the depen-
dence on Hsp90 for conformational stability.16 In addition,
Akt has been described as an Hsp90 client,34 and mTOR-
mediated signaling has been reported as diminished by Hsp90
inhibition.35 Recent results indicate that Hsp90 inhibition
overcomes limitations of irreversible EGFR inhibitors in
mutant EGFR/T790M cells, causing more complete suppres-
sion of the entire EGFR-PI3K-Akt-mTOR-p70S6K signaling
axis. This is accomplished by reduced expression of EGFR,
with associated reduction in phospho-Akt, and by reduced
mTOR signaling resulting in reduced S6 phosphorylation.36
Both 17-AAG and the water soluble 17-dimethylamin-
oethylamino-17-demethoxygaldanamcyin (17-DMAG) have
been tested in murine models of lung adenocarcinoma driven
by EGFR L858R-T790M. 17-AAG demonstrated activity
against these tumors, manifested by EGFR degradation, in
vivo radiologic responses by magnetic resonance imaging,
and histologic evidence for treatment effect.32 In the case of
17-AAG, responses were transient, attributed to its short
half-life and hepatotoxicity, which affected the dosing sched-
ule. 17-DMAG also produced antitumor activity with tumor
regressions of brief duration.36 Notably, 17-DMAG reduced
S6 phosphorylation in residual tumor cells, consistent with
suppression of the EGFR-mediated signaling axis. These
murine models should be useful for a direct comparison of
17-AAG or 17-DMAG with other Hsp90 inhibitors, as well
as for direct comparisons of Hsp90 inhibitors with irrevers-
ible EGFR inhibitors, with or without mTOR inhibitors, and
may help prioritize treatments in patients with NSCLCs
harboring EGFR T790M mutations.
EGFR vIII Mutation
The EGFR vIII in-frame deletion of exons 2 to 7 occurs
commonly in glioblastoma, where gefitinib and erlotinib have
shown only limited efficacy. EGFR vIII mutations are present
in approximately 5% (3 of 56) of squamous cell lung carci-
nomas, and like kinase domain-mutant EGFR, tissue-specific
gene expression of EGFR vIII in mice leads to the develop-
ment of NSCLC.37 EGFR vIII also interacts with the Hsp90
chaperone, suggesting Hsp90 inhibition as a strategy for this
subset of NSCLCs as well.38
HSP90 INHIBITION IN EGFR WILD-TYPE NSCLC
NSCLC Harboring ErbB2 Mutation
Other subsets of NSCLCs expressing wild-type EGFR
may also be dependent on Hsp90 client kinases for viability.39
Recently, in a series of 394 adenocarcinomas, 11 were found
to harbor an ErbB2 mutation, targeting residues homologous
to those affected by exon 20 insertions in EGFR.40 Mutations
included G776insV_G/C, which is found in the NCI-H1781
NSCLC cell line, and YVMA 776–779ins. In NCI-H1781
cells, ErbB2 is constitutively active in a ligand-independent
fashion and drives EGFR phosphorylation as well. NCI-
H1781 cells are resistant to erlotinib but sensitive to HKI-
272, which causes dephosphorylation of both ErbB2 and
EGFR in these cells.41 Wild-type ErbB2 is a client extremely
sensitive to degradation after Hsp90 inhibition.22 Interest-
ingly, mutant ErbB2 associates more strongly with Hsp90
than wild-type ErbB2, but this association is disrupted by
brief exposure to 17-AAG, resulting in mutant ErbB2 degra-
dation and loss of viability in addicted NSCLC cells.24
NSCLC Harboring Other Activated Kinases
NSCLCs may also depend on activated B-Raf or acti-
vated c-Met for viability, both documented Hsp90 client
kinases.11,12,42–44 B-Raf is activated by mutation in approxi-
mately 3% of lung adenocarcinomas,45,46 usually non-V600E
mutations that prevent Akt-mediated phosphorylation and
down-regulation of B-Raf activity. The chaperone depen-
dence of lung cancer-derived B-Raf mutants has not been
determined. Similarly, c-Met may be activated by gain-of-
function mutation, resulting in deletion in the juxtamembrane
domain,47,48 or by gene amplification, identified in 4% of lung
cancers.49 c-Met amplification defines lung and gastric cancer
cell lines dependent on the c-Met kinase for growth and
survival in vitro, suggesting that Hsp90 inhibitor-mediated
c-Met degradation may be therapeutically useful in this group
of tumors.50,51 In addition, c-Met amplification accounts for
approximately 20% of TKI resistance in NSCLCs harboring
EGFR kinase domain mutation, such that there is codepen-
dence on mutant EGFR and c-Met unresponsive to the inhi-
bition of either kinase alone.52 Hsp90 inhibition would be
expected to result in degradation of both mutant EGFR and
c-Met and so again may be of benefit after the failure of
gefitinib or erlotinib. Finally, cyclin-dependent kinase 4
(cdk4), another Hsp90 client, is amplified in approximately
3% of NSCLC,49,53 potentially representing a subset prone to
proliferative arrest after Hsp90 inhibition.
NSCLC Expressing Activated IGF-1R
Recently, insulin-like growth factor 1 receptor (IGF-
IR) activation has been shown to confer resistance to erlotinib
in NSCLC cells.54 In the EGFR wild-type NCI-H460 and
NCI-H1299 cells, erlotinib induced phosphorylation of IGF-
IR, which formed a heterodimer with EGFR to activate Akt
and mTOR, resulting in de novo protein synthesis of EGFR
and survivin. Inhibition of IGF-IR activation, suppression of
mTOR-mediated protein synthesis, or knockdown of survivin
expression abolished resistance to erlotinib and induced ap-
optosis. Because Hsp90 inhibition can affect IGF-IR expres-
sion,35,55 and expression of mTOR-related signaling proteins,
subsets of EGFR wild-type cells may be rendered erlotinib-
sensitive through Hsp90 inhibition.
POTENTIAL SYNERGISM OF HSP90
INHIBITORS WITH OTHER MOLECULAR
AGENTS
Other Agents that Disrupt Chaperone Function
Histone deacetylase 6 (HDAC6) is a cytoplasmic, mi-
crotubule-associated member of the class II family of HDACs
that possesses -tubulin deacetylase activity.56,57 HDAC6
also deacetylates Hsp90; small interfering RNA (siRNA)-
mediated depletion of HDAC6 induces Hsp90 acetylation,
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inhibiting its binding to ATP and to client proteins, which are
depleted by proteasomal degradation.58,59 HDAC6 also plays
a larger role in the management of the misfolded protein
stress response by recruiting aggregates of misfolded proteins
that are not efficiently degraded by the proteasome to dynein
motors for transport to structures known as aggresomes.60
Cells that lack HDAC6 do not form aggresomes properly and
fail to clear misfolded protein aggregates, which themselves
are toxic. Therefore, HDAC6 inhibition is expected to cause
misfolding of Hsp90 clients, resulting in cell death if they are
degraded in cells that depend on them for viability61–63; in
addition, if misfolded clients aggregate, inhibition of HDAC6
prevents aggresome formation, allowing the aggregates to
induce cellular toxicity. Recently, the HDAC6 inhibitor
LBH589 has been shown to induce Hsp90 acetylation, with
reduced association of Hsp90 with mutant EGFR, Akt, and
STAT3 and depletion of these proteins. Apoptosis selectively
occurred in EGFR mutant NSCLC cell lines.64 Synergism of
LBH589 with erlotinib was demonstrated, suggesting that
Hsp90 inhibitors and HDAC6 inhibitors may also demon-
strate cytotoxic synergism.
Proteasome inhibition may also disrupt chaperone func-
tion. The nonselective accumulation of cellular proteins may
overload the capacity of Hsp90 to fold proteins in the cytosol,
reducing the overall availability of Hsp90 and compromising
the stability of the most chaperone-dependent cellular ki-
nases. The accumulation of cytosolic proteins also inhibits
the ability of the endoplasmic reticulum (ER) to sort, fold,
and transport proteins.65,66 Under conditions of ER stress,
ER-specific chaperones are induced, including Grp78 and
Grp94, which may bind and trap chaperone-dependent ki-
nases, an event associated with the termination of translation,
the release of caspase 4, and the ultimate proteasomal or
lysosomal degradation of trapped proteins.67,68 Bortezomib
has demonstrated a low rate of response in NSCLC,69 but
correlation with EGFR mutation has not been investigated.
Synergism with Hsp90 inhibition has been demonstrated in
models of multiple myeloma, results that could extend to
EGFR-mutant NSCLC.
Modulation of Hsp70 Activity
Hsp90 inhibitors have been shown to universally in-
duce expression of Hsp70. This is caused by disruption of the
association of Hsp90 and heat shock factor 1 (HSF-1), allow-
ing its nuclear localization and binding to heat shock ele-
ments (HSEs) in the hsp70 promoter. Hsp70 itself is a
powerful chaperone that helps cells to cope with increased
concentrations of unfolded or denatured proteins. Hsp70 is a
potent inhibitor of apoptosis at multiple levels.70,71 At the
premitochondrial level, Hsp70 inhibits stress-activated ki-
nases, such JNK1. Hsp70 also prevents mitochondrial mem-
brane permeabilization through the blockage of Bax translo-
cation. At the postmitochondrial level, Hsp70 interacts with
both apoptosis-inducing factor72 and apoptosis protease acti-
vating factor (Apaf-1),73,74 preventing the recruitment of
procaspase-9 to the apoptosome, and also protects essential
nuclear proteins from caspase 3-mediated cleavage. The cy-
toprotective effects of Hsp70 suggest that its inhibition may
sensitize cells to Hsp70-inducing stimuli, such as Hsp90
inhibition. In leukemia models, abrogation of Hsp70 induc-
tion by siRNA or by the benzylidene lactam compound
KNK437, which attenuates the binding of HSF-1 to HSEs in
the hsp70 promoter, leads to increased apoptosis induced by
17-AAG.75
The expression of hsp70 messenger RNA in response to
cellular stress has been linked to the activity of cyclin-
dependent kinase 9 (cdk9), also known as positive transcrip-
tion elongation factor b.76 The C-terminal domain of RNA
polymerase II, which contains tandem repeats of the hep-
tapeptide YKSPTSPS, is phosphorylated by cdk9 at Ser2,
which couples transcriptional elongation with 3-end process-
ing. Inhibition of cdk9 reduces Ser2 phosphorylation, reduces
transcriptional elongation, and impairs 3-end processing,
leading to the rapid degradation of messenger RNAs that are
particularly cdk9 dependent.77,78 Flavopiridol is the most
potent known inhibitor of cdk979–81 and has been shown to
impair hsp70 messenger RNA accumulation in response to
heat.76 These results suggest that flavopiridol or other cdk9
inhibitors may prevent the induction of Hsp70 in response to
Hsp90 inhibition and may further sensitize cells to apoptosis
induced by Hsp90 inhibition.82
HSP90 INHIBITION IN SCLC
Unlike Hsp70, Hsp90 is not a general inhibitor of
apoptosis. However, it has recently been shown that Hsp90
assumes this role in SCLC cells.83 In SCLC cells, including
those refractory to chemotherapy, Hsp90, and not Hsp70,
negatively regulates Apaf-1, which is required for caspase
activation. Upon Hsp90 inhibition, Apaf-1 is released from
binding to the chaperone, but not degraded, leading to for-
mation of the Apaf-1-caspase 9 apoptosome complex. This
complex is activated by cytochrome c release, which occurs
when Hsp90 inhibition causes degradation of Akt (an Hsp90
client), resulting in BAD dephosphorylation and its release
from 14-3-3 proteins so that it can heterodimerize with Bcl-2
family members or activate proapoptotic Bax, leading to
mitochondrial depolarization. Therefore, Hsp90 inhibition
reduces Akt levels, causing cytochrome c release, and re-
moves negative regulation of Apaf-1 so that it can bind to
caspase 9, a complex poised for activation by cytochrome c.
These two events conspire to induce substantial apoptosis in
SCLC cells both in vitro and in vivo and suggest that this lung
cancer subset should be tested in trials of Hsp90 inhibitors.
STATUS OF HSP90 INHIBITORS
Geldanamycins
Several phase 1 trials of 17-AAG have been reported
using a variety of schedules.84 Initially weekly schedules
were examined.85–87 Modulation of Hsp90 targets was dem-
onstrated in peripheral blood leukocytes and in posttreatment
tumor biopsies, including depletion of Raf-1 in four of six
patients, and cdk4 depletion and Hsp70 induction in eight of
nine patients.85 However, it was not possible to reproducibly
demonstrate changes in biopsy specimens taken 5 days after
treatment. The lack of a sustained pharmacodynamic effect
prompted evaluation of twice-weekly dosing and five times
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daily schedules.88–93 Dose-limiting toxic effects have in-
cluded reversible elevations of transaminase levels, hyperbi-
lirubinemia, nausea, vomiting, diarrhea, headache, and ab-
dominal pain. Some of the nonhepatic toxic effects may be
attributable to dimethyl sulfoxide- or Cremophor-based for-
mulations required.
The poor solubility of 17-AAG prompted chemical
modification that resulted in 17-DMAG (Kosan), a water-
soluble analogue with properties desirable for formulation
that is also orally bioavailable.14,94–96 In addition, the synthe-
sis of a highly soluble hydroquinone hydrochloride derivative
of 17-AAG, IPI-504 (Infinity), recently has been report-
ed.97,98 IPI-504 rapidly converts to 17-AAG in human plasma
in a pH and oxygen-dependent manner. Moreover, in a
cellular setting, there is also an enzymatic conversion of
17-AAG to IPI-504, so that not only is IPI-504 a water-
soluble 17-AAG analogue, it is also an active 17-AAG
metabolite. Both 17-DMAG and IPI-504 maintain high bind-
ing affinity to human Hsp90, inhibit the growth of cells
overexpressing Hsp90 clients such as ErbB2, and cause
induction of Hsp70, all consistent with Hsp90 inhibition.
17-DMAG and IPI-504 have entered phase 1 trials. Intrave-
nous 17-DMAG has been tested in weekly, twice-weekly, and
daily dosing schedules.99–101 IPI-504, used in a twice-weekly
schedule 3 weeks of every four, has been well tolerated.102
Although stable disease was documented in the early
clinical experience, responses in solid tumors were not ob-
served. This finding suggests it may be most worthwhile to
test Hsp90 inhibitors in cancer types dependent on the more
sensitive Hsp90 client kinases, including Her2-positive breast
cancer. This population is indeed the focus of current 17-
AAG and 17-DMAG studies. In combination with trastu-
zumab, 17-AAG has produced partial and minor responses
and extended disease stabilization in patients with trastu-
zumab-refractory Her2-positive metastatic breast cancer.103
In addition, 17-DMAG has demonstrated activity in 3 of 13
patients with refractory acute myelogenous leukemia, where
Flt3 is a client kinase.101 The initial development of IPI-504
in solid tumors has adopted a similar strategy and has focused
on imatinib-refractory, c-kit-dependent gastrointestinal stro-
mal tumors. Metabolic responses have been seen in fluoro-
deoxyglucose positron emission tomography analysis, cor-
roborated by clinical observations such as resolution of
pleural effusions, reduction in hepatomegaly, and prolonged
stable disease.102 Taken together, these data indicate that the
geldanamycins are producing clinically meaningful antitumor
activity in a variety of settings. To date, few patients with
lung cancer have been treated with geldanamycins. Recently,
a phase 1/2 trial in advanced NSCLC has been launched, with
extended stable disease noted in patients positive for EGFR
mutation.104
Other Classes of Hsp90 Inhibitors
Limitations of the geldanamycin derivatives, including
off-target toxicity and formulation challenges, have prompted
the development of small molecule Hsp90 inhibitors. Other
classes of Hsp90 inhibitors have recently been extensively
reviewed.105 These include purine scaffold inhibitors106 that
are orally available, including CNF-2024 (Conforma), and
diarylpyrazole compounds such as the 3,4 diarylisoxazole
NVP-AUY922/VER-52296, discovered through structure-
based drug design.107 Compounds in purine and pyrazole
classes have high potency and have favorable properties,
including activity in 17-AAG resistant cell lines and inde-
pendence of P-glycoprotein, respectively. These and other
small molecule inhibitors are in early phase 1 development,
where pharmacodynamic end points, including client target
depletion and Hsp70 induction, are being analyzed. The
multiplicity of Hsp90 client kinases on which NSCLCs may
depend for viability and the antiapoptotic role of Hsp90 in
SCLC suggest that Hsp90 inhibitors merit evaluation in
multiple lung cancer populations.
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